Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GRM6 | O15303 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.36 |
| ▸ | USP8 | P40818 | 1/20 | 0.35 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8090040 | 0.82 | TRPV4 (0.39) | GAAGFERLMNAGRM6KDM4E | |
| SCHEMBL10120481 | 0.78 | CYP1A2 (0.37) | GAAGFERLMNAKDM4EUSP8 | |
| SCHEMBL29196717 | 0.78 | TRPV4 (0.37) | GAAGFERLMNATRPV4ADORA2A | |
| SCHEMBL1622094 | 0.78 | KDM4E (0.39) | LMNAGRM6KDM4EADORA2AHSD17B10 | |
| SCHEMBL9575173 | 0.77 | GRM6 (0.41) | LMNAGRM6KDM4EADORA2AHSD17B10 | |
| SCHEMBL9575176 | 0.75 | ALDH1A1 (0.43) | GRM6KDM4EADORA2AHSD17B10ADRA2A | |
| SCHEMBL406265 | 0.75 | KDM4E (0.37) | GAAGFERLMNAGRM6KDM4E | |
| SCHEMBL8388503 | 0.75 | GRM6 (0.36) | LMNAGRM6KDM4EADORA2AHSD17B10 | |
| SCHEMBL6379593 | 0.75 | GRM6 (0.36) | LMNAGRM6KDM4EADORA2AHSD17B10 | |
| SCHEMBL27401021 | 0.75 | GRM6 (0.36) | LMNAGRM6KDM4ETRPV4ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3121164-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2020-02-19 | — | — | EP | disclosed |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-06 | — | — | US | disclosed |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-10-29 | — | — | US | disclosed |
| EP-2997011-B1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-08-29 | — | — | EP | disclosed |
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-24 | — | — | US | disclosed |
| US-9884818-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-02-06 | — | — | US | disclosed |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | EVOTEC INTERNATIONAL GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| EP-3121164-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2017-01-25 | — | — | EP | disclosed |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2016-04-28 | — | — | US | disclosed |
| EP-2997011-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | Janssen Sciences Ireland UC (IE) | 2016-03-23 | — | — | EP | disclosed |
| WO-2015082324-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-11 | — | — | WO | disclosed |
| WO-2014184350-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN R&D IRELAND (IE) | 2014-11-20 | — | — | WO | disclosed |
| US-20120232073-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORPORATION | 2012-09-13 | — | — | US | disclosed |
| US-20120232073-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORPORATION | 2012-09-13 | — | — | US | disclosed |
| US-20120232073-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORPORATION | 2012-09-13 | — | — | US | disclosed |
| WO-2011062885-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141905-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | GAA 3815/4885GFER 1368/4885LMNA 2665/4885 |
| US-10457638-B2 | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | RB1, XDH, HBS1L | GAA 3815/4885GFER 1368/4885LMNA 2665/4885 |
| US-20170174668-A1 | SULFOXIMINE SUBSTITUTED QUINAZOLINES FOR PHARMACEUTICAL COMPOSITIONS | NEK5, NEK2, SIK2 | GAA 2574/4885GFER 3556/4885LMNA 3737/4885 |
| US-20200039931-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | GAA 3815/4885GFER 1368/4885LMNA 2665/4885 |
| US-20160115125-A1 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | RB1, XDH, HBS1L | GAA 3815/4885GFER 1368/4885LMNA 2665/4885 |
| US-20120232073-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GCGR, GPR4 | GAA 2673/4885GFER 4212/4885LMNA 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.